Sacklers Drained Purdue Money After First Lawsuit

Purdue Pharma and three executives pleaded guilty in 2007 and taking part in misleading the public about the risks of OxyContin. The Sacklers, who own the company, began to drain money from the company shortly after, according to the BBC. Between 2008 and 2017, the family transferred about $10.7 billion out of Purdue Pharma. The amount of money greatly exceeds withdrawals that the family made - $1.3 billion - between 1995 and 2007. Lawsuits Threaten the Company’s Survival In the past nine years, states, cities, and counties have started to sue Purdue for their misdeeds. At last, most of the lawsuits were added together in court. Now U.S. Bankruptcy Judge Robert Drain of White Plains, New York, will soon decide to decide whether to approve a $12 billion settlement. The payout would cover more than 2,700 lawsuits over its role in the opioid addiction crisis. The payout will potentially bankrupt the company, but they still have pharmaceutical companies that may remain unaffected and do business overseas. On May 10,…

Continue Reading

Hydromorph Contin Causing Heart Damage, Infections

Four years ago, the Ontario government decided to ban the use of Oxycontin, hoping to stop the pattern of increased opioid addiction in the province. Unfortunately, like every place banning Oxy, the medical profession needed another drug to take its place. Today, it appears that the drug most used is Hydromorph Contin. And now doctors say it’s causing deadly heart infections. What is Hydromorph Contin? Hydromorphone Contin is chemically similar to Oxycontin, but it’s meant to be harder to abuse, and it’s formulated mostly for people experiencing severe, acute pain such as those from accidents like car crashes or cancer. The drugs itself was designed to deter abuse and prevent injection by turning into a thick, gel-like substance when exposed to water. How Are People Getting Hurt? Unfortunately, if there is a will, there’s a way, especially when it comes to people with addiction finding new ways to use their drug of choice. Authorities say addicted persons looking to get their fix have discovered a dangerous workaround for Hydromorph…

Continue Reading

Insurers Crack Down on Dental Opioid Prescriptions

A recent study revealed that for many teens, opioid abuse begins with wisdom tooth extractions. The unnecessary prescriptions can lead to lifelong addiction, progressing to other opioid usages including heroin addiction. And now, insurers are discouraging opioid use for dental extractions, asking doctors to rely on Tylenol instead. The study, published in JAMA Internal Medicine last December, found that youths age 16 to 25 who first used opioids after dental care were more than ten times more likely than their peers to be diagnosed with opioid abuse. Startlingly, opioid use disorder often emerges within just a year of getting their first prescription. The Kansas City Star spoke with United Healthcare’s chief dental officer Ted Wong, who said that the relationship between dental prescriptions and opioid abuse makes sense. He explained that adolescents are more sensitive to drugs like opioids because their brains are developing. Opioid prescriptions for wisdom tooth procedures are common for young people, and nearly 5 million people have their wisdom teeth removed every year. “That gave…

Continue Reading

Controversial Fentanyl Test Strips Now Available

Many drugs that are sold on the street have been tainted with fentanyl, a powerful drug that is 80 to 100 times stronger than morphine. For some users, the tainted drug is too powerful. A controversial test strip that can test for fentanyl can save lives, but some people aren’t too excited about it. Why Test for Fentanyl? Fentanyl is taking lives faster than any drug before it, and many users accidentally ingest fentanyl when a drug is laced with it. Harm reduction advocates, who afvocate for spafe spaces and less strict drug laws, say this can save countless lives. The Fentanyl test strip technology was originally developed by a Canadian biotech company BTNX for urine drug testing. The dru strips, however, also work in liquid heroin or when a water is added to empty baggies of cocaine. In other words, it can test for the presence of fentanyl in liquids. Researchers at Johns Hopkins and Brown University determined the test strips can even detect a small amount of…

Continue Reading

Blue Cross Stops Covering Oxy Jan. 1st, Offers Abuse-Deterrent Opioids

A few months ago, Blue Cross/Blue Shield, one of the nation's largest health insurers, announced that they would stop covering Oxycontin, a drug known for its addictive properties as well as its manipulation of doctors through marketing. The makers of Oxy, Perdue Pharma, have also stopped marketing the drugs to doctors, perhaps as a result of dozens of lawsuits stemming from the opioid addiction crisis here in the US. While many people hail this as a good sign, the Blue Cross/Blue Shield coverage of pain relievers aren’t going to stop doctors from prescribing the medication in its generic form, or other variations of opioids in its place. A closer look at the changes that Blue Cross is making shows that the company isn't necessarily shunning opioids. They still plan to cover oxycodone, the active ingredient in OxyContin. Instead, they plan on shifting coverage to new formulations designed to be harder to abuse. Two New Drugs Blue Cross is Covering RoxyBond is short-acting (SA) oxycodone formulation with what the FDA…

Continue Reading

Perdue Pharma Will Profit From Medication-Assisted Treatment

Perdue Pharma makes Oxycontin, one of the most addictive prescription opioid drugs on the market. They’re a subject of many lawsuits and have been under Congressional investigation for their activities promoting opioid medications to doctors and other medical professionals. Many people say their company has made hundreds of millions of dollars fueling the addiction epidemic. However, the company has now started to dig into a new way to make money from the opioid epidemic. They’ve been quietly working to patent a new form of buprenorphine, a drug that is regularly used to help people get off of opioids. What is Perdue’s New Addiction Medication? In the recovery community, buprenorphine better known as a medication-assisted treatment when people take these drugs to stay clean. Perdue’s version is a “fast-acting” form of buprenorphine, which helps control drug cravings, according to CBS reported. While other versions of the drug are available in either tablet or dissolving strips, the Purdue version comes in a "wafer" that dissolves in only a few seconds.  …

Continue Reading

Lucemyra: FDA Approves New Medication-Assisted Treatment

Lucemyra has been on the market in the UK to assist with opioid withdrawal symptoms for about twenty years, but its use in the US has only just been approved. The FDA cleared the drug last Wednesday via fast-track to give American doctors another tool for fighting the opioid epidemic. Lucemyra alone is not to be considered treatment for opioid use disorder, the FDA says. However, clinical trials prove that it can reduce the severity of withdrawal symptoms that patients experience when they cease opioid use completely. This can give a person with an opioid use disorder a lifeline to help them get clean once and for all. Combined with therapy, 12-step programs and other tools, Lucemyra can help people find their way to recovery without the torment of many withdrawal symptoms. FDA Commissioner Dr. Scott Gottlieb says that this makes the drug an important tool that warranted quick approval. "The physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help and ultimately…

Continue Reading

Sublocade, New Med FDA-Approved for Opioid Abuse Disorder

Last week, the FDA announced approval of a once-a-month drug, Sublocade, for individuals with an opioid use disorder who need drug-assisted treatment to get and stay clean. For people suffering from the opiate-related disorders, there are just a few options for drug-related therapy to help them reduce cravings and stay clean. Suboxone and methadone have been the most available forms, but each has its drawbacks, including the fact that methadone is regulated in a way that means it must usually be dispensed just a dosage at a time. Missing a dosage can cause awful withdrawal symptoms and cravings. Even something as simple as inclement weather such as snow can make it difficult for drug treatment clients to get the medication they need. Suboxone has become popular because it has fewer drawbacks, with one of the main complaints being that a person prescribed the pill must be consistent with its dosage, taking it once a day, at the same time every day. This is why Sublocade, just approved by the…

Continue Reading

Addiction Treatment Under AHCA

Five hundred thousand Americans have died from opioid addiction in the last 15 years According the U.S. Centers for Disease Control and Prevention (CDC). The amount of deaths is four times that of the previous fifteen years. This an American crisis of addiction to opioids and the problem is only getting worse.  Because of this increase in use of opioids the issue has made it's way into the forefront of American policy. Financial Dilemma Meanwhile, with the growing number of addicts, the availability of resources for recovery become less attainable and more costly. This creates a new financial dilemma that is hanging over the heads of the addicts in our communities and puts  pressure onto the policy makers in government. Lack of Coverage The severity of these issues then brings into question the Trump Era’s health care policies and his team’s ability to confront this epidemic. The forecast is grim considering this new administration’s policy towards the healthcare of Americans. There is a substantial lack of coverage for people with pre-existing conditions and…

Continue Reading

Pros and Cons of Bunavail Approved by FDA

Pros  Twice the bioavailability of Suboxone  Promising alternative to methadone  Treatment includes psychiatric therapy Cons Causes respiratory issues Can cause death Bio Delivery Sciences International’s new drug application has reached the final phase of approval by the FDA. Their supplemental application (sNDA) for Bunavail can step out of the management phase for opioid addiction patients and begin the use of the drug for treatment of opioid addiction. Bunavail has twice the bioavailability of Suboxone film, which has increased it’s marketability ten fold and and therefore an attractive alternative for bottom line of the manufactures.   Bioavailability -  the proportion of a drug or other substance that enters the circulation when introduced into the body. When a drug is injected it has 100% bioavailability. Other means of administration have less than 100% bioavailability such as oral methods. Bunavail will be administered to patients that are just beginning recovery from opioid dependency. This is a major step in the right direction for the addicts who seek a break from dependency that may…

Continue Reading